BofA analyst Jason Gerberry lowered the firm’s price target on Immunovant (IMVT) to $38 from $45 and keeps a Buy rating on the shares. The firm ...
New research at the University of Alberta may make it easier to diagnose serious diseases that disrupt the body's energy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback